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CHAPTER ONE

INTRODUCTION

1.1 BONE ANATOMY

Not all bone is growing, and not all bone is hard and dense. Within the long bones
of the body such as the femur, tibia, radius, or ulna, there are two distinct types of bone;
compact cortical bone, and spongy trabecular, or cancellous, bone. These bones are
broken up into three anatomical sections: the epiphysis, metaphysis, and diaphysis
(Figure 1.1). The epiphysis is the end of the bone where it forms a joint with other bones,
cartilage, tendons, and muscles. The epiphysis is also where the growth plate is located
and where most all new growth and lengthening of the long bones occurs. The
metaphysis is the junction between the growing end of the bone and the long hollow shaft
which makes up the center portion of the bone, the diaphysis.
Cortical bone is hard and compact, made of lamellar crosslinked mineralized
collagen fibers, or lamellae. These lamellae form concentric rings around blood vessels,
with their fibers oriented in opposite directions for strength, which become known as
vascular sinuses, and sinusoids as they continue out into the trabecular portions of the
bone.
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Figure 1.1 The anatomy of a long bone. Shown here are the segments of a bone. The
center long part of a bone is the diaphysis. The intermediate part between the long shaft
and the growth plate is the metaphysis. The growth plate and the joint end of the bone is
known as the epiphysis. Also shown are the two main distinct types of bone; cortical, the
hard outer layer of lamellar cross grained tough bone, and trabecular, or “spongy” bone.
The vascular sinusoids (blood vessel channels) are also shown coming from the center of
the shaft into the growing end of the bone (Shupp et al., 2018).
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The lamellae also form rings around the outside of the sheathed sinusoidal bundles in
concentric sheets of circumferential lamellae, with the collagen fibers again oriented in
different directions for strength.
Trabecular bone is softer, sponge-like in appearance, much more porous with
open pockets, or trabeculae, throughout. The medullary cavity of a bone is lined with
trabecular bone. The ends of long bones, at their epiphyses, are made up primarily of
trabecular, spongy bone tissue. Human vertebrae and mandibles are other examples of
trabecular bone with no cortical bone tissue. Vertebrae are frequently used to gauge bone
health by measuring their bone mineral density (BMD).

1.2 BONE REMODELING

Human bones undergo constant remodeling. The five stages of bone remodeling
include the resting stage, activation stage, resorption stage, reversal stage, and formation
stage. After formation of new bone and before activation of osteoclasts to break down the
bone is a resting stage, where osteocytes live as new cells and metabolize minerals and
collagen. During activation stage osteoclasts are signaled to the bone surface to be
resorbed. This is done through cytokine signaling which can thereby be turned on and off.
At the resorption stage osteoclasts form a bubble over the bone surface and produce an
acidic micro-environment which dissolves the calcified collagen matrix of the mature
bone. When the reversal stage begins the osteoclasts are turned off and osteoblasts are
directed to the area to start to rebuild bone. This is also a function of cytokine signaling
and can be hormonally induced. During the formation stage osteoblasts metabolize
collagen and this is deposited in a matrix formation where it is mineralized by
3

hydroxyapatite. Hydroxyapatite is calcium phosphate and crystallizes into the calcium
crystals that make bone hard and dense. The collagen is a tough substrate for crystal
formation, and its patterning adds strength to lamellar cortical bone areas (Gallagher and
Tella, 2014).

1.3 MINERAL HOMEOSTASIS

There are 1000 g of calcium in the average human body, with 99% of this calcium
bound in the mineral matrix of bones and teeth. The other 1% (10 g) is found in the
plasma, intracellularly, and in soft tissues. Calcium homeostasis is rigidly maintained in
the blood and this is accomplished by 1% of the 990 grams of bound crystallized calcium
(9.9 g) of the bones being available for resorption into the bloodstream whenever needed.
Calcium is necessary for most all muscle and nerve functions, cell division and growth,
cell membranes, protein synthesis, and many other cellular functions. Therefore, it is
helpful that the body can borrow it from the bones when needed. However, if signals tell
the bones to constantly resorb calcium then osteoporosis can be a real threat. Problems
with calcium absorption in the intestines, as well as problems with eliminating too much
calcium from the kidneys can both lead to low bone density. Vitamin D aids the
efficiency of absorption of calcium in the intestines and colon (Favus and Goltzman,
2008).
Phosphorus is used in most all cells of the body to aid in energy production,
storage, and transport. It is also an essential element for cell membranes. The
phosphorylation and dephosphorylation of many enzymes and transcription factors are
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their cues to activation/inactivation. Phosphate also combines with calcium to make
calcium phosphate and this is what hardens onto the collagen fibers produced by
osteoblasts. Magnesium is also used by all cells of the body. It is necessary for glycolysis
and the citric acid cycle and is used by the cells in production energy in the form of ATP
(Garfinkel and Garfinkel, 1985). It is also essential for proper heart rhythm and blood
pressure, and it is essential for bone metabolism. Magnesium helps balance calcium
signaling in the cell and maintains chemo-osmotic balance at the cell membrane, both
intra-and extra-cellularly. Additionally, magnesium is essential in many other metabolic
and enzymatic reaction pathways (Jahnen-Dechent and Ketteler 2012). About 60% of the
body’s magnesium is housed in the bones, with approximately one third in the outer
cortical bone and the hydration layer directly surrounding the periosteum tissue on the
exterior of bones. The other two-thirds of the body magnesium is primarily thought to be
housed in the crystalline hydroxyapatite- collagen matrix (Castigliani et al., 2013).
Magnesium deficiencies can lead to lowered BMD (Orchard et al., 2014) supposedly
through improper crystallization, and by reducing A recent study in the United Kingdom
points to the benefits of magnesium supplement intake for bone health (Welch et al.,
2017).

1.4 OSTEOPOROSIS AND ITS CAUSES

Recent studies estimate over 10.2 million adults above age 50 suffer from
osteoporosis, and approximately 44 million adults above age 50 suffer from low bone
density, or osteopenia (Wright et al., 2014). Osteoporosis is defined by the World Health

5

Organization as a “progressive systemic skeletal disease characterized by low bone mass
and microarchitectural deterioration of bone tissue, with a consequent increase in bone
fragility and susceptibility to fracture” (Kanis et al, 1994). This leads to fractures and
breakage of bones. These injuries can alter the course of a person’s life and are a very
serious matter. Some fractures, such as hip fractures, are linked to higher rates of
morbidity and mortality thereafter. A recent study found the mortality rate 12 months
after a hip fracture to be 21.3% (Diamantopoulos et al., 2013). Other possible outcomes
include the use of a cane or walker, use of a wheelchair, and bedridden, not to mention
pain and depression from the newfound lack of mobility.
There are many bone and mineral disorders which affect bone density.
Osteomalacia is one such condition which is distinguishable by lack of mineralization of
the collagen matrix by hydroxyapatite. Vitamin D is used to combat this condition, as it
has been found to be deficient in most osteomalacia patients. Vitamin D aids in the
absorption of calcium by the intestines and is usually included in medications for
osteoporosis patients. Phosphate deficiencies (hypophosphatemic osteomalacia) and
magnesium deficiencies also cause osteomalacia and osteoporosis (Castiglioni et al.,
2013). Other rarer conditions have seen osteomalacia result from fluorosis and from overconsumption of aluminum (Kiely et al., 1999).
Problems with overactive parathyroid gland (hyperparathyroidism) can also lead
to osteoporosis because parathyroid hormone (PTH) signals bones to release calcium into
the bloodstream, and this occurs through resorption of bone mineral matrix by
osteoclasts. If this goes on unabated it can lead to calcium deficiencies and lessened
mineralization of bone matrix, which leads to lowered BMD and increases fracture risk.

6

Thyroid hormones are known to be essential for proper bone homeostasis (Bassett
and Williams, 2016). Calcitonin is produced by the thyroid gland and acts in opposition
to PTH. Calcitonin is known as an antiresorptive and prevents bone resorption and
subsequent calcium release. Calcitonin has been shown effective at increasing BMD in
osteoporotic patients and those with osteopenia (Binkley et al., 2014), but little is
understood about how exactly calcitonin effects bone metabolism.
Leptin is another important hormone with a sympathetic nervous system pathway
which has been shown to affect the hypothalamic pituitary peripheral neuroendocrine
axes, including the thyroid, gonadal, cortisol and growth hormone axes. These all affect
bone growth and remodeling through endocrine signaling (Upadhyay et al., 2015). Leptin
has been shown to positively impact bone mass and metabolism and acts in opposition to
serotonin (Yadav et al., 2009).
Another endogenous chemical known to impact bone mass is neuromedin-U (NMU). It is
activated through sympathetic pathways and is thought to be a part of the leptin pathway
of bone regulation. Cocaine and amphetamine-regulated transcript (CART), a
neuropeptide precursor protein, has also been shown to be a part of hypothalamic boneregulation (Driessler and Baldock, 2010), and this has interesting implication for this
study.
Elevated levels of secreted endogenous cortisol have also been linked to lowered
bone density (Chiodini and Scillitani, 2008). There are numerous other conditions which
can affect bone density and growth, including several genetic defects, such as osteogenia
imperfecta and marfans syndrome which can affect the many hormones, receptors, or
cytokines responsible for bone metabolism. In the case of osteogenesis imperfecta the
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osteoblasts do not make sufficient quantities of collagen and the bones form to be very
brittle. All of these conditions deserve their own research.
There are also several medicines known to cause drug-induced bone loss, and in
some cases even osteoporosis. Some of these medicines include: glucocorticoid steroids
(prednisone, hydrocortisone, etc.), selective serotonin reuptake inhibitors (SSRI) and
selective norepinephrine inhibitors (SNRI) prescribed as anti-depressants and antianxiolytics, aromatase inhibitors (used to cease production of estrogen in postmenopausal women with breast cancer), proton pump inhibitors (common antacids),
anticonvulsants, medroxyprogesterone acetate (Depo-Provera™ birth control) (Lopez et
al., 2014), thiazolidinediones (insulin sensitizers used to treat type-2 diabetes), heparin
(used to treat blood clots), calcineurin inhibitors (immuno-suppressants used for severe
dermatological conditions and transplant rejections), gonadotropin releasing hormone
agonists (used particularly for prostate cancers), and some other cancer chemotherapies
(Panday et al., 2014). Also on the list of drugs negatively affecting bone density are the
anti-virals like tenofovir™, which are commonly prescribed to HIV patients. Studies
have shown that approximately 15% of patients using these drugs will lose ≥ 6% of their
BMD over a 48-week treatment period (Stellbrink et al., 2010). The prognosis for
patients taking glucocorticoid steroids is even worse, with most developing bone loss
very rapidly, over the course of only a few months of therapy (Compston, 2018).
The glucocorticoids (GC) are particularly insidious towards bone density and
fracture risk. They act by over-stimulating osteoclasts to promote drastic bone resorption.
They are particularly harmful to the trabecular bone of the vertebrae. They induce
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osteocyte apoptosis, which can lead to “brittle” bones which fracture more easily even
before reduced BMD is detected.
Glucocorticoids also inhibit osteoblast differentiation by inhibiting their precursors.
These detrimental effects all add up to take a major toll on bone mass and strength
(Panday et al., 2014). The resultant condition is called glucocorticoid-induced
osteoporosis (GIO).

1.5 OSTEOPOROSIS TREATMENTS

Treatments for osteopenia and osteoporosis include: bisphosphonate therapy,
parathyroid hormone therapy, calcitonin therapy, estrogen and other hormone therapies
(Cosman et al, 2014), among others. Osteoporosis is especially prevalent in postmenopausal women, and men over age 50. One would suspect a link to hormones in this
correlation, especially estrogen, since this is what post-menopausal women stop
anabolizing. Estrogen therapy was the first line of treatments used once this correlation
was found in the 1960s’s (Gallagher and Tella, 2014). After a scare caused by reports of
increased incidence of breast cancer among estrogen therapy patients, which were later
proven to be untrue for pure estrogen supplements alone, the predominant treatment
option switched to bisphosphonate therapies which have since been shown to reduce
fractures in osteoporosis patients by as much as 50% (Gallagher and Tella, 2014).
According to Adler et al., at the time of their published research in 2016, bisphosphonate
treatments were still the most commonly used treatment for osteoporosis. Other than
some reported abdominal discomfort it is generally a well-tolerated medication.
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Calcium and phosphorous supplements have been shown to have increase bone mass and
strength in murine experiments (Friedman et. al, 2011). Excessive phosphorous intake,
however, has been shown to be damaging, and decrease bone metabolism as well as
hinder other metabolic processes (Vorland et. al, 2017).
Sex hormones, both estrogens and androgens, have been found to be protective
against osteoporosis and fractures. The primary animal model used for osteoporosis
laboratory testing is the ovariectomized rat model. This causes the rat to stop production
of estrogen and induces osteoporotic bone loss (Komori, 2015). Indeed, estrogen and
androgens in both males and females have been linked to most all stages of bone growth
and maintenance (Almeida et al., 2017).
Hormone therapies are used to control osteoporosis in patients with hormonal or
metabolic diseases. Parathyroid hormone can be regulated with parathyroid suppressant
drugs, or a parathyroidectomy. Calcitonin can be boosted by stimulating the thyroid in
patients with hypothyroidism.
Receptor activation of nuclear factor kappa-B ligand (RANK-L) therapies
involves blockading the RANK-L receptors. RANK-L causes transcription and release of
Interleukin- 2 (IL-2) which brings an onslaught of osteoclasts to that area and resorption
results. This is a relatively new area of treatment. The most recently published research
seems to show that low-dose pulsed administration of RANK-L to mice actually
increases bone mass and BMD, but this is an area that is not yet well-understood as it is
also known that sustained high cellular levels RANK-L cause bone resorption as
mentioned above (Cline-Smith, 2016).
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1.6 PHYSICAL ACTIVITY AND BONE DENSITY

According to the National Osteoporosis Foundation, 20% to 40% of peak adult
bone mass can be determined by lifestyle choices and behaviors (Weaver et. al, 2016).
Amount and type of exercise are the primary lifestyle choices discussed, as well as
calcium, phosphate, and vitamin D intake levels. Numerous studies have been carried out
using the standardized Bone-Specific Physical Activity Questionnaire (BPAQ) to assess
past, current, and overall lifetime activity levels and types of activities, which are scored
according to their intensities (Weeks and Beck, 2008). Proper amount and types of
exercise during peak bone formation years is key to healthy bone density levels in later
adult life. Assessments of college aged females in South Korea have shown a positive
correlation between physical activity scores (using BPAQ) and fat-free mass (FFM) to
femoral and lumbar spine BMD, as determined by dual x-ray absorptiometer (DXA)
scans (Kim et. al, 2016; Kim et al., 2018). The American College of Sports Medicine
recommends that adults perform weight-bearing exercise and raise the heartrate daily for
bone health (Kohrt et al., 2004).

1.7 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Attention deficit hyperactivity disorder (ADHD) has a long history and everchanging heterogenous etiology and clinical presentation. It was first mentioned over 200
years ago in British medical papers, and as a modern psychological condition when the
term “brain-injured child” was coined in the 1920’s. This was soon after the Spanish Flu
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epidemic when a huge number of cases of encephalitis were seen in children, which
caused a host of post brain injury psychiatric problems. It was discovered in the 1930’s
that these children, diagnosed with minimal brain dysfunction (MBD), responded very
well to doses of amphetamine (AP) (Bradley, 1937). The term “minimal brain
dysfunction” (MBD) was then being used to describe hyperactive and overly impulsive
children. Bradley’s publications led to further studies by prominent psychiatrists of the
era, including several which examined the effects of amphetamine on learning and testtaking in high school and college-aged students (Bradley and Bowen, 1940; 1941;
Molitch and Sullivan, 1937; Andrews, 1940; Thornton and Holck, 1939; Simonson and
Enzer, 1941; Flory and Gilbert, 1943; Minkowsky, 1939). After their studies in the early
1940’s this is what Bender and Cottington had to say about amphetamine therapy for
childhood psychiatric disorders, “…it is worth emphasizing again that the successful use
of this drug in the behavior problems of children depends on a clear understanding of the
causes of the child's problems, the proper choice of children to receive the drug, and the
use of the drug only as an adjunct to adequate personal psychotherapy, tutoring and social
adjustments” (Bender and Cottington, 1942). Unfortunately, their advice fell on deaf ears
and family doctors and pediatricians in the U.S. routinely prescribe psychostimulants to
children as young as 4 years old to treat ADHD, with no additional counseling,
psychotherapy or extra tutoring prescribed (DSM-V, 2013). Dr. Charles Bradley
conducted prolific testing and research on children with behavioral problems and
psychiatric problems using amphetamine and methylphenidate from the late 1930’s into
the 1950’s (Bradley, 1937; 1940; 1941; 1950). This was the beginning of the psycho
stimulant neuro-pharmaceutical era of the current age.
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In the 2nd edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-II) (American Psychiatric Association (APA) 1968), “hyperkinetic reaction of
childhood” was first used to describe the condition now known as ADHD (Matthews et
al., 2014). In 1980, the DSM-III (APA, 1980) changed the name of the condition to
Attention Deficit Disorder (ADD) and added the symptoms of impulsivity,
inattentiveness, and hyperactivity to better describe the condition. The DSM-IV
(APA,1994) started to characterize the disorder into 2 subgroups, ADHD-I, with
inattentiveness as the main symptom, and ADHD-C, with combined hyperactivity and
impulsivity as the symptoms. The DSM-V (APA, 2013) breaks up the classification
system into one or the other or both. In other words, a person can be ADHD inattentive,
ADHD hyperactive, or ADHD combined. A person must experience a range of symptoms
and they must have occurred for at least 6 months and be interfering with multiple
aspects of a person’s life (work, school, family, etc.).
There have been numerous tests developed to characterize the different types of
ADHD. Both psychological tests and neuroimaging tests using magnetic resonance
imaging (MRI) and positron emission tomography (PET) have seemingly been able to
distinguish between and characterize ADHD and control groups, and to some extent
between types of ADHD patients (Nagel et al., 2011; Sigurdardottir et al., 2016; Vanicek
et al., 2014).
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1.8 ADHD TREATMENTS

Treatments for ADHD began in the 1950’s with Benzedrine™ and Dexedrine™,
both amphetamines (AP). Once it was discovered that methylphenidate (MP), sold under
the brand name of Ritalin™, was also a potent psychostimulant it began to be prescribed
for the so-called “minimal brain injury” children (Bradley, 1950). Methylphenidate is
currently used for children and adults diagnosed with ADHD, as well as for treating
narcolepsy, giggling, incontinence, weaning patients off ventilators, and alleviating the
stress and depression associated with cancer and HIV (Volz, 2008).
The 1990’s saw a surge in diagnosis of ADHD and prescription of
pharmacological drugs for its treatment. This was due mainly to the new classifications of
the disorder in the DSM-IV published in 1994. Methylphenidate was marketed as
Ritalin™ and saw a surge in sales in the 1990’s. Slight molecular changes have allowed
for the development of a few methylphenidate derivatives that have made it to market as
well.
Methylphenidate works in much the same way as cocaine does in the brain,
increasing extracellular levels of dopamine and epinephrine by blocking their re-uptake
transporters. Methylphenidate is being studied as a possible drug to alleviate the
symptoms of cocaine addiction and reduce the impulsivity of addicts (Konova et al.,
2013), and has been shown to have neuro-protective activity when taken in conjunction
with methamphetamine. This is proposed because methylphenidate has been shown to
reduce oxidative stress in the neurons of the brain when given before a dose of
methamphetamine, and a few mechanisms have been proposed as to why this is
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happening. Either the methylphenidate is binding to the same receptors as
methamphetamine and blocking its effects, or the methylphenidate aids the cleanup
efforts of the cell and places excess dopamine into vesicles and slows the production of
dopamine and somehow minimizes the excess dopamine which can oxidize to harmful
molecules when present in excess (Volz, 2008).
During the 1990’s several new prescription medications were developed for the
treatment of ADHD. Among the most popular and effective were the amphetamine salts,
like Adderall™ and Vyvanse™. This was basically a return to the 1950’s Benzedrine™
and Dexedrine™ (amphetamine) treatments.
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Figure 1.2 Molecular structures of dextro- and levo-amphetamine stereoisomers.
The only difference in these molecules is the orientation of the methyl group. As with
most pharmaceuticals, this can provide differences in drug strength and effect, with the lisomer showing better results for inattention, and the d-isomer for impulsivity (Sagvolden
T and Xu T. 2008).
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Figure 1.3 Molecular structure of methylphenidate, sold as Ritalin™. Notice the
difference in structure from the amphetamines in Figure 1.2.
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Indeed, dexamphetamine, or Dexedrine™, has seen an upsurge as an ADHD
pharmaceutical treatment option. Adderall™ has been the other extremely popular brand
and it contains a 3:1 dextro to levo (d to l) mixture (Figures 1.2 and 1.3). The newer
extended release formulas also contain a mixture of the two isomers.
There is a plethora of psychostimulant drugs to choose from when choosing a
pharmaceutical option for treating ADHD. Most all of them are simply amphetamine
salts with varying ratios of levo (left) and dextro (right) isomers. Research has found that
the d-isomer is more potent and more effective at stimulating dopamine while the l
isomer is more effective at stimulating noradrenaline. Methylphenidate is normally
marketed as a racemic mixture of its d & l enantiomers. In 2001, dexmethylphenidate was
approved by the FDA, claiming a wide variety of benefits over the racemic mix,
including smaller necessary doses and no lack of bioavailability if taken with meals (Liu
et al., 2006).
There is a growing list of non-stimulant ADHD medications currently being
prescribed as well. Studies also continue to be carried out on a wide variety of nutritional
and herbal supplements which may aid in the treatment of ADHD, including clinical
trials and literature reviews of Omega-3 polyunsaturated fatty acid (Agostoni et al., 2017;
Changa et al., 2018; Matsudaira et al 2015; Toshiko et al., 2017), and trials comparing the
effects of Passiflora incarnata extract to methylphenidate in ADHD children
(Mohammadi et al., 2005).
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1.9 PURPOSE AND HYPOTHESIS

Clinical research at the New York State Psychiatric Institute outpatient center
found that amphetamine has equal potential for abuse as methamphetamine among
addicts in a randomized double-blind crossover study (Kirkpatrick et al., 2012). Testing
of 46 male methamphetamine addicts at a national hospital in the Republic of Korea
found that methamphetamine addicts had a higher rate of osteoporosis and osteopenia in
the spine and a significantly lower BMD than 188 of their healthy peers (Kim et al.,
2009). It was discovered, in a 2016 analysis of a meta-survey of the health of the citizens
of the United States of America, called the National Health and Nutrition Examination
Survey (NHANES), that youth who were taking prescription stimulant medications had a
significantly lower bone mineral density (BMD) and bone mineral content (BMC) in their
vertebrae and femur, as measured by dual x-ray absorptiometer (DXA), than their peers
who were not taking the psychostimulant medications (Feuer et al., 2017). Another study
found that young rats exposed to methylphenidate experienced lower BMD and reduced
strength in appendicular bones (Komatsu et al., 2012).
Studies have shown that a large percentage of children with ADHD have vitamin
deficiencies, particularly iron, magnesium, zinc and vitamin D, and it has been proven
without a doubt that vitamin D and magnesium are required for proper bone growth
(Villagomez and Ramtekkar, 2014; Sharif et al., 2015). Recently, beta-adrenergic
receptors have been discovered on osteoblasts and their functionality when bound with
noradrenaline has been seen to increase the intracellular levels of c-AMP which activates
the genes for RANK-L (Ma et al., 2013), which has been proven to degrade bone mineral
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and cause lowered BMD (Cline-Smith, 2016). It has been seen that amphetamines
stimulate the release of norepinephrine preferentially to dopamine (Rothman et al., 2001),
although dopamine has been found to be released in greater ratios by methylphenidate
(Volkow et al., 2001).
As of the writing of this manuscript, there has not been a clinical DXA bone
density study of young adult (19–27 years old) ADHD patients who use prescribed
psychostimulants. With looming osteoporosis troubles affecting the entire world’s
population, in addition to the more and more widespread use of psychostimulant
medications to treat ADHD patients as young as four years old, this study seems
necessary to see if we are trading our youth’s bone mass in exchange for better mental
focus and alertness. Based on the previously cited research literature, it is hypothesized
here that there will be statistically significant differences between bone densities of the
ADHD patients using the psychostimulants and their healthy peers, with the users of the
medications having significantly lower BMD than the healthy control subjects.
Additionally, male and female cohorts will be compared to look for differences.
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CHAPTER TWO

METHODS

2.1 EXPERIMENTAL DESIGN
This experiment was designed as a clinical comparison study. The two groups
being compared were college-age young adult (19–27 years old) ADHD patients taking
prescription stimulant medications containing amphetamine or methylphenidate, and
college age subjects who had never taken such prescription psychostimulants. The sample
size was a total of 66 subjects, 13 of which were excluded from final analyses for various
exclusion criteria, leaving a total of 53 subjects in the final analysis (Results). Of the
subjects, 28 were part of the control group (CON) and had never used psychostimulants
of any kind, for any reason. The other 25 subjects were the experimental group (EXP),
and this group was further divided into the amphetamine (AP, n = 15), and
methylphenidate (MP, n = 10) groups dependent on which drug the subjects were
prescribed.
The subjects were recruited from the campus of The University of Alabama in
Huntsville (UAH) Huntsville, AL. The project was advertised by using flyers and mass
emails. During the last two months of the project, $25 gift cards were made available by
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Dr. Shannon Mathis. When potential study subjects responded via email, a scripted
response was given and then an appointment was set up if they were still interested in
participating. Potential subjects came to the DXA research laboratory in Wilson Hall, on
the campus of UAH. Subjects were asked to review and sign a consent form, then they
were given a questionnaire. Those with diabetes, osteoporosis or other metabolic bone
diseases, bulimia, anorexia, regular cigarette smokers, heavy drinkers (more than 4 drinks
per day), kidney or liver disease, celiac disease, multiple myeloma, lupus, cancer,
rheumatoid arthritis, rickets, hyper or hypoparathyroidism, Paget's Disease, osteogenesis
imperfecta, osteomalacia, Perthes’ disease, hip dysplasia, osteomyelitis, or any other
disease affecting bone growth and density, and persons weighing over 150 kg were
precluded from participating in the study. Additionally, any female volunteers who state
they have not had a menstruation in three or more weeks were excluded until after their
next menstruation to ensure no one was pregnant. No pregnant or nursing mothers were
used for this study.
Data from 53 subjects were analyzed for the final analyses, the others were
eliminated due to being prescribed non-stimulant ADHD medications, because they had
previously taken the stimulant medication but were not currently taking anything for 12
months or more, or because they had been on the medication for less than 12 months,
total. The two African American control subjects were cut from the study because there
were no African American experimental participants to compare them with, and the bone
densities of people of recent African ancestry are known to be greater than that of
Caucasians (Hochberg, 2007).
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Only the principal investigator (PI) had any correspondence with any potential
subjects, through email and verbal conversation. All subjects were given a numerical
identifier once they were accepted for the study. Only the PI has the files with the
subjects’ names and identifiers, and these notebooks and files are locked in a filing
cabinet in a locked room on the campus of UAH. They will be stored there for 5 years,
then destroyed through the university’s confidential document disposal service company.

2.2 RESEARCHERS AND PRELIMINARY CONCERNS

The principal investigator for this study was Kirk Lawson, graduate student in the
Biological Sciences department at UAH (author). His faculty co-advisors for the project
were Dr. Shannon Mathis, a professor in the Kinesiology department at UAH, and Dr.
Gordon MacGregor, a physiology professor in the Biological department at UAH.
Before any study could commence, a two-day Hologic DXA manufacturer’s
training course, “QDR for Windows Application Training”, was attended (a corporate
representative was sent to the UAH campus) and online classes were fulfilled, in addition
to literature research on DXA in general.
The Collaborative Institutional Training Initiative (CITI) training course for researchers
dealing with human subjects was completed, and an online HIPAA course was also
completed. A detailed proposal was submitted to the Institutional Review Board for
human research at UAH, and approval was granted after some clarifications and some
requested additional precautions were addressed (see Appendix I). In addition, a detailed
methodology was reported to the UAH radiation safety chair, and approval was obtained
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from the Alabama Department of Health; Alabama State Radiation Safety Committee.
Dr. Kirk Holdsambeck acted as the physician safety advisor and liaison, and Ms. Holly
Crowson, a radiology technician at a local Huntsville, Alabama radiology group,
provided additional training on the DXA scanner in respect to positioning subjects on the
table properly.
The exposure and absorbed dose levels of the DXA bone density scans are
approximately 1/25 of the limits allowed for in NRC (Nuclear Regulatory Commission)
regulations (10CFR20: subpart D). These regulations may be accessed at the NRC
website. The PI was responsible for recording the radiation dose for each scan for each
participant and created a database in order to record participant ID, scan date, scan type,
and radiation dose. At study closure, the PI provided the deidentified database to the
Radiation Safety Office.
The radiation doses from the manufacturer, Hologic Inc., are listed below for the
Hologic Horizon A Model. This is governed by the system software by control of the
speed (in seconds) and length (in inches) of each scan.
AP spine-Array mode, 0.13 mGy; AP spine-fast array mode, 0.07 mGy; spineexpress mode, 0.04 mGy; Hip Array mode, 0.13 mGy; Hip fast array mode, 0.07 mGy;
Hip express mode, 0.04 mGy; Full body scan, 0.008 mGy; Forearm scan, 0.035 mGy.
The PI was responsible for ensuring that radiation limits of 1mSv per year were not
exceeded, and participants were not present in the same room while other participants
were being scanned. The lowest possible radiation setting was used for each participant.
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2.3 EQUIPMENT USED

When subjects arrived at their appointment in the DXA lab, their weight and
height were measured using a SECA stadiometer. A consent form and a three-page
questionnaire were provided to each subject and an investigator remained present to
answer any questions. Once it was confirmed that the subject qualified for the study,
based on the questionnaire, the DXA scans were administered, using the Hologic dual
energy x-ray absorptiometer (Bedford, MA). The Hologic model Horizon A,
S/N 300511M, was used for this research. Manufacturer protocols were followed, and
scans were only conducted by the Primary Investigator. The DXA was calibrated daily,
prior to scans and data collection.

2.4 THE DXA SCANS

All subjects were asked to put on hospital scrubs and remove all metal objects
from their bodies to assure uniformity. No subjects with metal implants applied for the
study. The scans involved lying down on a padded table which is not enclosed. An arm
passed over the area to be scanned and then the procedure was over, and the table and
arm positioned themselves for ease of exiting of the subject. Each scan took 1-3 minutes.
There were no noises or lights. Three areas of the body were scanned for this study. Hip
scans were performed on the left femur head and greater trochanter areas. Spinal scans
were performed examining the 2nd through 5th lumbar vertebrae. Whole body scans
involved scanning the full body.
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2.5 THE DXA REPORT

The DXA report gives a variety of body composition information such as: body
fat percentage, lean percentage, BMI, compartmental breakdown of fatty and lean tissue,
percentile compared with peers (AM, or age-matched) and compared with young-normal
(YN) averages for body composition results, and many more options. The NHANES
BCA (body composition analysis) calibration was used, which refers to the updated
calibration of all DXA software after the NHANES study found the machines to be
underestimating body fat by approximately 3 percent. The report also gives the BMC and
BMD of the total body and of individual body parts and compartments.
These measurements are compared statistically to NHANES data to give a t-score which
is drawn from comparison to young normal NHANES results, and a z-score which is
derived from comparison to age-matched NHANES results. A YN percentile is given as
well as the Age-matched AM percentile.
The DXA scanner was able to accurately determine the weight and body
compositions of the subjects tested. The scanner also gave an accurate body-fat, lean
mass, and bone mineral content (BMC) measurement. These were used to determine BMI
and lean indexes using Excel.
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2.6 HYPOTHESIS

It is hypothesized that there will be statistically significant differences between
bone densities of the ADHD patients using the psychostimulants and their healthy peers
with the users of the medications, the EXP group, having significantly lower BMD than
the healthy CON subjects. The EXP group will be further subdivided into AP and MP
groups, to determine if there are any differences in lowered BMD between each of these
groups and compared to the CON group. It is hypothesized that the AP group will have
greater bone-loss than the MP group. For further analytical benefit, the data from the
different sexes will also be compared.

2.7 STATISTICAL ANALYSES METHODS

The BMD data obtained from the DXA scans of the hip, femur neck, lumbar
spine, and whole-body were used to compare the EXP group with the CON group. The zscores from the BMD data were also used for statistical analyses. Microsoft Excel was
used to record all data into spreadsheet format. Next, Graph Pad Prism 8 was used to
statistically analyze all the data, which were imported from Excel, and make all charts
and graphs. Descriptive statistics were obtained, t-tests were run to obtain t and P values
of the EXP and CON groups. Next, ANOVA tests were used to compare the 3 groups
(AP, MP, CON) and obtain F and P values. These values were used to determine if there
were statistically significant differences between the groups. If the P-value obtained was
< 0.05, this was considered a statistically significant difference and additional post-hoc
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tests were run. These were Tukey multiple analysis tests and were used to determine
more precisely where was the difference, between which groups, AP, MP, and CON.
Ages were compared with a Mann-Whitney test using Graph Pad Prizm software.
Height, weight, BMI (kg/m²), percent body-fat, and lean-indexes (BMC + lean mass/
height²) were calculated with Microsoft Excel, then analyzed with Graph Pad Prizm using
ANOVA analyses to compare Control with AP and MP groups. Tukey multiple analyses
were conducted to compare sexes, and compared the same sexes to each other, since there
is a difference in percent body fat between males and females, with females typically
containing more fat in the breast and hip areas.
Physical activity was assessed using questionnaires and calculated according to
BPAQ official instructions (Weeks and Beck, 2008). Past, current, and total BPAQ scores
were evaluated. Only the total BPAQ scores were used in the final analyses. Percent
body-fat, body mass index (BMI), lean index, and relative skeletal muscle index (RSMI)
were all measured and/or calculated using Excel and the Hologic DXA reports.
Hologic software, based on NHANES data from thousands of previously recorded
scans, was used to calculate z-scores. The z-score is basically the standard deviation of a
subject’s BMD from that of age, sex, and ethnicity matched peers. A z-score of 0 means a
subject is in-line with the average BMD. A positive z-score such as +1 or +2 means a
subject is 1 or 2 standard deviations above their peers’ BMDs. A negative z-score of -2
means a subject is 2 standard deviations below the average BMD of their peers. This
stage of bone density loss is the onset of Osteoporosis and is called Osteopenia. A z-score
of -2.5 or below means a subject is suffering from Osteoporosis, and significant bone
loss.
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Bone mineral density (BMD) is the most commonly used measurement for
measuring bone health and thickness. It is useful for predicting the likelihood of fractures
and can alert physicians to the deterioration of trabecular bone mass. Bone mineral
density was assessed for femur neck, hip, lumbar spine, and whole body using the
Hologic Horizon DXA scanner. Bone mineral content (BMC) was also measured and
used for the calculation of lean indexes.
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CHAPTER THREE

RESULTS

3.1 PARTICIPANTS

A total of 53 subjects participated in this study. The CON group contained 28
subjects and the EXP group contained 25 subjects. There were 31 male subjects and 22
female subjects. The ages of the study participants were between 19 and 27 years old.
The average age of both the CON and EXP groups was 21 years.
The height analysis showed that the male amphetamine group had lower average
height compared to the other male groups when analyzed by one-way ANOVA, F (2, 28)
= 4.15, P = 0.03. The mean heights of the male amphetamine, control, and
methylphenidate groups were 173.6 ± 5.0 cm (n = 8), 179.8 ± 5.8 cm (n = 17), and 181.7
± 6.7 cm (n = 6). Tukey multiple comparison analysis showed that the average height of
the male amphetamine group was significantly lower than both the male methylphenidate
group and the male control group (P = 0.04 and P = 0.05, respectively). The female
control and male methylphenidate groups showed no difference in average height (P =
0.78). One-way ANOVA showed no difference overall between the heights of the
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control, amphetamine, and methylphenidate subjects, F (2, 50) = 0.95. P = 0.40. The
mean heights were 173.0 ± 11.1 cm (n = 28), 167.8 ± 11.6 cm (n = 15), and 171.8 ± 14.6
cm (n = 10), respectively. Likewise, no differences were discovered with ANOVA of the
heights of female control, amphetamine or methylphenidate groups, F (2, 19) = 0.39, P =
0.68, with mean heights of 162.6 ± 8.9 cm (n = 11), 161.1 ± 13.8 cm (n = 7), and 157.0 ±
9.0 cm (n = 4), respectively.
One-way ANOVA showed no difference between the weights of the control,
amphetamine, and methylphenidate groups, F (2, 50) = 0.02, P = 0.98, with average
weights of 76.42 ± 15.25 kg (n = 28), 75.78 ± 22.56 kg (n = 15), and 75.24 ± 16.98 kg (n
= 10), respectively. No difference was discovered in the ANOVA of the weights of the
female control, amphetamine, and methylphenidate groups, F (2, 19) = 0.42, P=0.66, or
between the male control, amphetamine, and methylphenidate groups, F (2, 28) = 0.63,
P=0.54.
One-way ANOVA of the average percent body fat for the control, amphetamine,
and methylphenidate groups showed no difference between the groups,
F (2, 50) = 1.30, P = 0.28, with average percent body fat for the groups of 32.3 ± 8.9%
(n = 28), 36.8 ± 7.8% (n = 15), and 35.2 ± 10.8% (n = 10), respectively. Further ANOVA
of the female and male groups’ mean body fat percentage showed a small difference
between these groups, F (2, 19) = 1.81, P = 0.19 and F (2, 30) = 2.68, P = 0.08,
repectively.
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Table 3.1 – Table showing matching characteristics between control and
experimental subjects. No differences were seen (P > 0.05), except for activity levels
(BPAQ).

Age (years)
Height (cm)

Control
21
173.0

Experimental
21
169.4

Weight (kg)

76.42

75.56

BMI (kg/m²)

26.56

26.38

RSMI (kg/m²)

7.41

6.87

BPAQ*

32.45

16.56
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t-value
t=0.56, df=41
t=1.10,
df=47.85
t=0.17,
df=44.51
t=0.10,
df=49.75
t=1.36,
df=48.06
t=3.25,
df=46.71

P-value
0.58
0.28
0.86
0.92
0.18
0.01

3.2 BODY MASS INDEX, LEAN INDEX, AND RELATIVE SKELETAL MUSCLE
INDEX

One-way ANOVA of the average BMI from the control, amphetamine, and
methylphenidate groups showed there was no difference between the groups, F (2, 50) =
0.15, P = 0.86, and mean BMI of the groups were 26.5 ± 6.2 kg/m² (n = 28), 26.9 ± 7.4
kg/m² (n = 15), and 25.5 ± 5.2 (n = 10), respectively. Additional ANOVA of the BMI for
the female and male groups also showed no difference between groups F (2, 19) = 0.80, P
= 0.46 and F (2, 28) = 2.18, P = 0.13, respectively.
One-way ANOVA of the mean lean index of the control, amphetamine, and
methylphenidate groups also showed no difference between the groups, F (2, 50) = 1.88,
P = 0.16, and the lean index scores were 16.63 ± 2.38 kg/m² (n = 28), 16.10 ± 3.69 kg/m²
(n = 15), and 14.21 ± 5.04 kg/m² (n = 10), respectively. Further ANOVA of the mean
lean index scores of the female and male groups showed no difference between these
groups, F (2, 19) = 1.91, P = 0.17 and F (2, 28) = 0.62, P = 0.55, respectively.
The RSMI was calculated for the control, amphetamine, and methylphenidate
groups, and one-way ANOVA showed that there was no difference between the mean
RSMI scores of the groups, F (2, 50) = 0.94, P = 0.40, with mean RSMI scores of 7.41 ±
1.36 kg/m² (n = 28), 6.913 ± 1.70 kg/m² (n = 15), and 6.80 ± 1.372 kg/m²
(n = 10), resepctively. Further ANOVA of the female and male groups also showed no
difference in RSMI, F (2, 19) = 0.50, P = 0.61 and F (2, 28) = 0.62, P = 0.54,
respectively.
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3.3 PHYSICAL ACTIVITY COMPARISONS

One-way ANOVA of the average total BPAQ scores from the control,
amphetamine, and methylphenidate groups (Figure 3.1) showed that there was a
difference between the groups, F (2, 50) = 5.12, P = 0.01, and average BPAQ scores were
32.45 ± 21.33 (n = 28), 14.96 ± 13.34 (n = 15), and 18.95 ± 14.85 (n = 10), respectively.
Tukey multiple analysis showed the difference was between the control and amphetamine
groups, P = 0.01. Tukey comparison of the control and methylphenidate (P = 0.12) and
amphetamine with the methylphenidate (P = 0.86), showed no differences. The mean
BPAQ score for the female group also showed no differences when compared by
ANOVA, F (2, 19) = 1.63, P = 0.22, and the male group showed minor differences, F (2,
28) = 3.28, P = 0.05 (Figures 3.2 and 3.3), but the cutoff for these analyses was P < 0.05.
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Figure 3.1 One-way ANOVA of the average total BPAQ scores. Showed that the
experimental groups had lower activity scores than controls. F (2, 50) = 5.12, P = 0.01.
The control group average was 32.45 ± 21.33 (n = 28). The amphetamine group average
was 14.96 ± 13.34 (n = 15). The methylphenidate groups had an average BPAQ score of
18.95 ± 14.85 (n = 10). Tukey multiple comparison analysis showed the difference was
mainly between the control and amphetamine groups, P = 0.01. Comparison of the
control and methylphenidate showed no difference, P = 0.12. Likewise, comparison of
the amphetamine with the methylphenidate group showed no difference, P = 0.86.
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Figure 3.2 One-way ANOVA of the female total BPAQ scores. Showed no difference
between the groups. F (2, 19) = 1.63, P = 0.22. The mean BPAQ score for female control
group was 31.15 ± 18.55 (n = 11). The mean BPAQ score for the female amphetamine
group was 15.18 ± 16.81 (n = 7). The mean BPAQ score for the methylphenidate group
was 21.52 ± 22.03 (n = 4).
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Figure 3.3 One-way ANOVA of the male total BPAQ scores. Technically, these
statistics showed no statistically significant difference between groups, but P = 0.05 is
right on the assigned cutoff value. F (2, 28) = 3.28, P = 0.05. The male control group had
a mean BPAQ score of 33.28 ± 23.46 (n = 17). The male amphetamine group had a mean
BPAQ score of 14.77 ± 10.67 (n = 8). The male methylphenidate group mean BPAQ
score was 17.24 ± 9.85 (n = 6).
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3.4 Z-SCORES AND BMD FOR FEMUR NECK

One-way ANOVA of the average z-scores for BMD of the femur neck from the
control, amphetamine, and methylphenidate groups showed there was no difference
between the groups (Figure 3.4). F (2, 50) = 0.29, P = 0.75. The average z-score for
control group femur neck BMD was 0.3 ± 1.3 (n = 28). The average z-score for the
amphetamine group femur neck BMD was 0.05 ± 1.1 (n = 15). The average z-score for
the methylphenidate group femur neck BMD was 0.2 ± 1.1 (n = 10).
One-way ANOVA of the mean BMD of the femur neck area of the control,
amphetamine, and methylphenidate groups showed no difference between the groups
(Figure 3.5). F (2, 50) = 0.46, P = 0.64. The mean BMD of the femur neck of the control
group was 0.941 ± 0.171 g/cm² (n = 28). The mean BMD of the femur neck of the
amphetamine group was 0.895 ± 0.131 (n = 15). The mean BMD of the femur neck of the
methylphenidate group was 0.919 ± 0.144 (n = 10).
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Figure 3.4 One-way ANOVA of the average Z-scores of femur neck. No difference
seen between the groups. F (2, 50) = 0.29, P = 0.75. The average z-score for control
group femur neck BMD was 0.3 ± 1.3 (n = 28). The average z-score for the amphetamine
group femur neck BMD was 0.05 ± 1.1 (n = 15). The average z-score for the
methylphenidate group femur neck BMD was 0.2 ± 1.1 (n = 10).

39

P=0.64

BMD (g/cm2)

1.5

1.0

0.5

0.0
CON

AP

MP

Figure 3.5 One-way ANOVA of femur neck BMD. Showed no difference between
groups. F (2, 50) = 0.46, P = 0.64. The mean BMD of the femur neck of the control group
was 0.941 ± 0.171 g/cm² (n = 28). The mean BMD of the femur neck of the amphetamine
group was 0.895 ± 0.131 (n = 15). The mean BMD of the femur neck of the
methylphenidate group was 0.919 ± 0.144 (n = 10).
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3.5 Z-SCORE AND BMD FOR HIP

One-way ANOVA of the z-scores of hip BMD from the control, amphetamine,
and methylphenidate groups (Figure 3.6) showed no difference between the groups. F (2,
50) = 0.46, P = 0.63. The average z-score for hip BMD of the control group was 0.4 ±
1.2 (n = 28). The average z-score for hip BMD of the amphetamine group was 0.04 ± 0.9
(n = 15). The average z-score for hip BMD of the methylphenidate group was 0.2 ± 1.2 (n
= 10).
One-way ANOVA of the average BMD from the hip area of the control,
amphetamine, and methylphenidate groups showed no difference between the groups
(Figure 3.7). F (2, 50) = 0.58, P = 0.56. The average hip BMD for the control group was
1.049 ± 0.172 g/cm² (n = 28). The average hip BMD for the amphetamine group was
0.993 ± 0.127 g/cm² (n = 15). The average hip BMD for the methylphenidate group was
1.023 ± 0.174 g/cm² (n = 10). A Welch’s two-tailed t-test between the control and
experimental (AP and MP combined) also showed no difference, t=0.99, df=50.84, P =
0.32 (n = 28 and n = 25, respectively).
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Figure 3.6 One-way ANOVA of the z-scores of the hip area. Showed no difference
between the groups. F (2, 50) = 0.46, P = 0.63. The average z-score for hip BMD of the
control group was 0.4 ± 1.2 (n = 28). The average z-score for hip BMD of the
amphetamine group was 0.04 ± 0.9 (n = 15). The average z-score for hip BMD of the
methylphenidate group was 0.2 ± 1.2 (n = 10).
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Figure 3.7 One-way ANOVA of the average BMD from the hip area. No difference
was seen between the groups. F (2, 50) = 0.5835, P = 0.56. The average hip BMD for the
control group was 1.049 ± 0.172 g/cm² (n = 28). The average hip BMD for the
amphetamine group was 0.993 ± 0.127 g/cm² (n = 15). The average hip BMD for the
methylphenidate group was 1.023 ± 0.174 g/cm² (n = 10). A Welch’s two-tailed T-test
between the control and experimental (AP and MP combined) also showed no difference,
P = 0.32, t=0.99, df=50.84 (n = 28 and n = 25, respectively).
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3.6 Z-SCORE AND BMD FOR LUMBAR SPINE

An unpaired one-tailed student’s t-test comparing the control and experimental
groups’ average z-scores based on the lumbar spine BMD showed that there was a
difference between the groups (Figure 3.8), t = 2.08, df = 51, P = 0.02. The average zscore of the control group was 0.5 ± 1.4 (n= 28). The average z-score of the experimental
group was -0.3 ± 1.3 (n = 25).
One-tailed unpaired student’s t-test between the average BMD of the lumbar
spine of the control and experimental groups showed a difference between the groups
(Figure 3.9), t = 2.22, df = 51, P = 0.02. The average lumbar spine BMD of the control
group was 1.111 ± 0.154 g/cm² (n = 28). The average lumbar spine BMD for the
experimental group was 1.018 ± 0.151 g/cm² (n = 25).
One-way ANOVA of the average z-scores of the BMD at the lumbar spines of the
control, amphetamine, and methylphenidate groups showed no difference between the
groups (Figure 3.10). F (2, 50) = 2.67, P = 0.08. The mean z-score for the lumbar spine
BMD of the control group was 0.5 ± 1.4 (n = 28). The mean z-score for the lumbar spine
BMD of the amphetamine group was the lowest, at -0.5 ± 1.0 (n = 15). The mean z-score
for the lumbar spine BMD of the methylphenidate group was 0.06 ± 1.7 (n = 10).
One-way ANOVA of the mean lumbar spine BMD of the control, amphetamine,
and methylphenidate groups (Figure 3.11). With P = 0.06, F (2, 50) = 3.01, this test was
just above the P < 0.05 cut-off, so Tukey multiple comparison analysis was also
performed, and a difference was seen between the BMD of the control and amphetamine
groups, P = 0.047. No difference was seen between the control and methylphenidate
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groups, or between the amphetamine and methylphenidate groups with P = 0.6 and P =
0.55, respectively. The mean lumbar spine BMD for the control group was 1.111 ± 0.154
g/cm² (n = 28). The mean lumbar spine BMD for the amphetamine group was 0.992 ±
0.107 g/cm² (n = 15). The mean lumbar spine BMD of the methylphenidate group was
1.057 ± 0.201 g/cm² (n = 10). Additional Tukey analysis of the difference between the
female and male amphetamine and control groups (Figure 3.12) showed no difference
between either of these groups, P = 0.48 and P = 0.11, respectively.
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Figure 3.8 Lumbar spine z-scores t-test. A difference was seen between the groups.
t=2.08, df=51, P = 0.02. The average z-score of the control group was 0.5 ± 1.4 (n= 28).
The average z-score of the experimental group was -0.3 ± 1.3 (n = 25).
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Figure 3.9 Lumbar spine BMD t-test. Showed a difference between the groups. T =
2.215, df = 51, P = 0.02. The average lumbar spine BMD of the control group was 1.111
± 0.154 g/cm² (n = 28). The average lumbar spine BMD for the experimental group was
1.018 ± 0.151 g/cm² (n = 25).
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Figure 3.10 One-way ANOVA of the average z-scores of the lumbar spine. Did not
show a significant difference. F (2, 50) = 2.67, P = 0.08. The mean z-score for the lumbar
spine BMD of the control group was 0.5 ± 1.4 (n = 28). The mean z-score for the lumbar
spine BMD of the amphetamine group was the lowest, at -0.5 ± 1.0 (n = 15). The mean zscore for the lumbar spine BMD of the methylphenidate group was 0.06 ± 1.7 (n = 10).
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Figure 3.11 The BMD of the lumbar spine of the amphetamine group was lower
than the control group with Tukey multiple analysis. P = 0.047. With P = 0.06, F (2,
50) = 3.011, the one-way ANOVA of the entire group was right at the P = 0.05 cut-off, so
Tukey multiple comparison analysis was also performed. A difference was observed
between the amphetamine and control groups (P = 0.047). No difference was seen
between the control and methylphenidate groups, or between the amphetamine and
methylphenidate groups with P = 0.6 and P = 0.55, respectively. The mean lumbar spine
BMD for the control group was 1.111 ± 0.154 g/cm² (n = 28). The mean lumbar spine
BMD for the amphetamine group was 0.992 ± 0.107 g/cm² (n = 15). The mean lumbar
spine BMD of the methylphenidate group was 1.057 ± 0.201 g/cm² (n = 10).
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Figure 3.12 Additional Tukey analyses of female and male amphetamine and
control groups showed no differences. P = 0.48 and P = 0.11, respectively. Control
female average spine BMD was 1.127 ± 0.142 g/cm² (n = 11). Amphetamine female
average spine BMD was 1.028 ± 0.116 g/cm² (n = 7). The average control male spine
BMD was 1.101 ± 0.165 (n = 17). The average amphetamine male spine BMD was 0.959
± 0.094 (n = 8). The male amphetamine group was the only group with BMD < 1 g/cm².
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3.7 Z-SCORE AND BMD FOR WHOLE BODY

One-way ANOVA of the z-scores of the control, amphetamine, and
methylphenidate groups, based on the whole-body BMD, showed a difference between
the groups (Figure 3.13). P = 0.03, F (2, 50) = 3.61. The average z-score for the wholebody BMD of the control group was 0.5 ± 1.2 (n = 28) The average z-score for the
whole-body BMD of the amphetamine group was -0.5 ± 1.2 (n = 15). The average zscore for the whole-body BMD of the methylphenidate group was -0.3 ± 1.4 (n = 10).
Additional Tukey multiple comparison analysis was conducted, and the amphetamine and
control groups showed a difference, P = 0.04. The methylphenidate and control group
showed no difference, P = 0.21, nor did the amphetamine and methylphenidate groups to
one another, P = 0.91.
Welch’s unpaired one-tailed t-test of the BMD of the control and experimental
groups showed a difference was seen between the groups (Figure 3.14), t = 2.56,
df=50.99, P = 0.006. The average control whole-body BMD was 1.199 ± 0.118 g/cm² (n
= 28). The average experimental whole-body BMD was 1.120 ± 0.104 g/cm² (n = 25).
One-way ANOVA of the control, amphetamine, and methylphenidate groups’
whole-body BMD showed a difference between the groups (Figure 3.15). P = 0.03, F (2,
50) = 3.63. The average whole-body BMD of the control group was 1.199 ± 0.118 g/cm²
(n = 28). The average whole-body BMD of the amphetamine group was 1.105 ± 0.085
g/cm² (n = 15). The average whole-body BMD of the methylphenidate group was 1.143 ±
0.128 g/cm² (n = 10). Tukey multiple comparison analysis showed that there was a
difference between the control and amphetamine group P = 0.03, but not between the
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control and methylphenidate groups P = 0.37, or between the amphetamine and
methylphenidate groups P = 0.68.
Tukey multiple comparison analysis of whole-body BMD showed a that the male
amphetamine group had lower BMD than then the male controls, P = 0.04 (Figure 3.16).
The average male control whole-body BMD was 1.232 ± 0.123 g/cm² (n = 17). The
average male amphetamine whole-body BMD was 1.107 ± 0.088 g/cm² (n = 8). No
difference was seen between the control female and amphetamine female groups, P =
0.81. The average control female whole-body BMD was 1.148 ± 0.920 g/cm² (n = 11).
The average amphetamine female whole-body BMD was 1.103 ± 0.088 g/cm² (n = 8).
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Figure 3.13 Whole-body z-scores. A difference was seen between groups. F (2, 50) =
3.6 P = 0.03. The average z-score for the whole-body BMD of the control group was 0.5
± 1.2 (n = 28) The average z-score for the whole-body BMD of the amphetamine group
was -0.5 ± 1.2 (n = 15). The average z-score for the whole-body BMD of the
methylphenidate group was -0.3 ± 1.4 (n = 10). Additional Tukey multiple comparison
analyses were carried out and the significant difference was seen between the
amphetamine and control groups’ z-scores, P = 0.04. The methylphenidate and control
group showed no difference, P = 0.21, nor did the amphetamine and methylphenidate
groups to one another, P = 0.91. One-way ANOVA of the Z-scores of the control,
amphetamine, and methylphenidate groups, based on the whole-body BMD.
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Figure 3.14 Whole-body BMD t-test. A difference was seen between groups, t=2.59,
df=51, P = 0.006. The average control whole-body BMD was 1.199 ± 0.118 g/cm² (n =
28). The average experimental whole-body BMD was 1.120 ± 0.104 g/cm² (n = 25).
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Figure 3.15 Tukey analysis of whole-body BMD. ANOVA showed that there was a
difference between the groups. F (2, 50) = 3.627, P = 0.03. The average whole-body
BMD of the control group was 1.199 ± 0.118 g/cm² (n = 28). The average whole-body
BMD of the amphetamine group was 1.105 ± 0.085 g/cm² (n = 15). The average wholebody BMD of the methylphenidate group was 1.143 ± 0.128 g/cm² (n = 10). Tukey
multiple comparison analysis showed that there was a difference between the control and
amphetamine group P = 0.03, but not between the control and methylphenidate groups P
= 0.37, or between the amphetamine and methylphenidate groups P = 0.68.
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Figure 3.16 Tukey multiple comparison analysis of female and male whole-body
BMD. Showed the male amphetamine group had lower BMD than then the male
controls, P = 0.04. The average male control whole-body BMD was 1.232 ± 0.123 g/cm²
(n = 17). The average male amphetamine whole-body BMD was 1.107 ± 0.088 g/cm² (n
= 8). No difference was seen between the control female and amphetamine female
groups, P = 0.81. The average control female whole-body BMD was 1.148 ± 0.920 g/cm²
(n = 11). The average amphetamine female whole-body BMD was 1.103 ± 0.088 g/cm²
(n = 8).
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CHAPTER FOUR

DISCUSSION

4.1 DISCUSSION

The results of this experiment support the hypothesis that young-adult
amphetamine stimulant ADHD medication users will exhibit lowered bone densities
when compared to their non-stimulant using peers. The lumbar spine is the primary
indicator region for osteoporosis and lowered BMD in this region is a tell-tale sign that
the stimulant medications are having an adverse effect on bone health. The lowered
height seen among the male amphetamine users is another strong indicator of adverse
effects on bone growth and elongation. While previous surveys found lower BMD in
ADHD patients’ femurs and vertebrae (Feuer et al., 2017), this present clinical study
found lowered BMD in the vertebrae and the whole-body overall. The previous
experimentation on rats (Komatsu et al., 2012), which showed lowered BMD after
methylphenidate exposure; observations of methamphetamine addicts (Kim et al., 2009),
which showed significantly lower BMD; statistical studies of the NHANES survey
(Feuer et al., 2017), which showed lowered BMD among children diagnosed with
ADHD; all led to the hypothesis of this study, which was then supported by statistically
significant data.
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4.2 IMPLICATIONS

This research could and should be the beginning of more in-depth studies into the
correlation and possible causation of bone loss from amphetamine use. The nonappearance of effects in the methylphenidate group’s lumbar spine and whole-body BMD
could be a vital clue about the negative pharmacological activity of the amphetamines, as
both are stimulants, but of differing molecular structures and pharmacological activity.
The amphetamine use correlation with lowered spinal BMD seems to resemble the effects
of corticosteroids more-so than methylphenidate does, therefore the hormonal
chemotactic routes of bone-loss should be further explored in relation to amphetamine
use. Additionally, the lack of negative effects on the height and whole-body BMD in the
female stimulant medication users should be another indicator of the pharmacological
pathways leading to bone loss in the males, although it is assumed that estrogen is
exhibiting it’s known protective effect on the bones of the females (Almeida et al., 2017).
However, this was not enough to prevent the female amphetamine users from showing
significantly lower bone density in their lumbar spines, like their male counterparts.
Testosterone is also known to protect BMD and there have been lowered testosterone
levels observed in male ADHD patients taking methylphenidate medications (Wang et
al., 2017), so perhaps these psychostimulants are interfering with testosterone levels in
both sexes.
Since the discovery of norepinephrine transporters (NETs) on osteoblast cells, it
has been hypothesized that a lack of NE in those cells leads to lowered BMD (Ma et al.,
2013; Zhu et al., 2018). An abundance of NE outside the cell, and very little being
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transported inside the cell seems to be the cause of the disruption of bone metabolism,
with increased resorption being the result. Amphetamine acts by stimulating the release
of NE as well as by blocking the re-uptake (Florin et al., 1994), and l-amphetamine has
been shown to increase extracellular levels of NE just as well as methamphetamine
(Kuczenski et al., 1995). This explains why the methamphetamine addicts studied in
Korea (Kim et al., 2009) and young adults in the United States taking prescription
amphetamine, (Feuer et al., 2017) both share the trait of lowered BMD. Some studies
seem to show that methylphenidate is more beneficial for learning skills and builds
neuroplasticity (Tye et al., 2010), and this drug releases more dopamine than NE.
Dopamine is thought to possibly be a mediator to the effects of NE (Kuczenski et al.,
1995).
The impact of psycho-stimulant ADHD medications on the bone-health needs to
be more carefully evaluated to determine if the benefits really outweigh the risks to bone
health and the risks to other physical and mental faculties from long-term stimulant use.
At the very least the mechanism of action of the bone-density diminishing effects of the
psycho-stimulant medications needs to be determined so counteractive measures can be
used, especially in children and young adults.

4.3 LIMITATIONS

This study had a few possible flaws. Only one university was represented, from
one city, in one state, so it was geographically limited. Second, the DXA scans took place
in the Kinesiology department DXA laboratory and many of the volunteer study subjects
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were students of this department and played sports and/or exercised regularly. This was a
trend throughout their lives, as was seen in the higher overall BPAQ scores. Additionally,
there were no African American volunteers for experimental subjects, so this ethnicity
was not represented in this study. Other than this, the study was meticulously planned so
as not to have many obvious flaws. It is expected to have good generalizability to young
adults.

4.4 FUTURE DIRECTIONS

Since poor bone health and low bone density and associated fractures are rising
worldwide, and particularly in the United States, and ADHD is one of the most diagnosed
psychiatric diseases among adolescents, it is of great importance to find long-term
medications for this disease which do not have harmful side-effects leading to increased
morbidity later in life. As a species we do not want to necessarily trade cognitive abilities
in our adolescence for adverse physical health and well-being in our elderly years. As
stated above, the results of this investigation warrant further research into the possible
hormonal disruption being caused by amphetamine stimulants, due to the significant
difference of lumbar spine BMD between control and amphetamine-using subjects. The
whole-body BMD comparisons show that there may be effects from the methylphenidate
as well, but they do not seem as pronounced as with the amphetamines. Psychostimulants
have been shown to increase glucocorticoid levels (Rouge-Pont et al., 1995), and both
pharmaceutical and excessive endogenous glucocorticoids are known to cause bone loss
very rapidly, in a dose-dependent manner (Compston, 2018; Zhou et al., 2013)
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Future directions of research should include a similar clinical comparison of
ADHD stimulant medication users with non-users with blood samples to look for
glucocorticoids, PTH, calcitonin, cortisol, leptin levels, estrogen and testosterone levels,
to determine if hormones are being affected by the stimulant medications. Tests for
RANK-L would also be appropriate (Cline-Smith et al., 2016). Blood tests should also
include vitamin and mineral levels to determine if there is a lack of vitamin D, calcium,
phosphates, magnesium, or other essential metabolites of bone remodeling. Imbalances in
these nutrients can lead to osteomalacia symptoms.
Discovering the mechanism of the bone-loss effects of these psychostimulants
will allow scientists to evaluate whether the risks can be averted with supplemental
therapies and nutrients, or whether the use of these high strength psychostimulants should
be discontinued in favor of safer medications.
Alternative therapies for ADHD, both pharmaceutical and cognitive behavioral,
are being developed and tested currently. Some of the most interesting of these new
treatments involve natural substances, like fatty acids and plant extracts (Ahn et al., 2016;
Bloch and Mulqueen, 2014). The benefits of exercise, especially cardiovascular exercise,
on ADHD symptoms has been studied in a review, and as those authors suggest, a formal
clinical study should be undertaken to determine just how effective this can be (Heijer et
al., 2017). It is wholeheartedly recommended that these alternative treatments be
explored and tested further, along with novel natural product-based treatments which
would signal the body to do things like boost calcitonin levels or “mop-up” excess
endogenous glucocorticoids. Nutritional supplements and increases of extracellular levels
of minerals (Salehi et al., 2016; Sharif et al., 2015; Villagomez and Ramtekkar, 2014)
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should surely be clinically studied as well. Most of these are being investigated as adjunct
therapies to be used in combination with the pharmaceutical psychostimulants, but they
could very well be effective treatments used alone, or in combination with one another.
The addition of MRI and PET scans to positively determine whether a patient really has
ADHD would also save a lot of misdiagnoses. The risks would have to be evaluated
against rewards here due to cost of MRI and radiation from PET.
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